vs
ExlService Holdings, Inc.（EXLS）とペナンブラ（PEN）の財務データ比較。上の社名をクリックして会社を切り替えられます
ExlService Holdings, Inc.の直近四半期売上が大きい（$542.6M vs $385.4M、ペナンブラの約1.4倍）。ペナンブラの純利益率が高く（12.3% vs 11.1%、差は1.2%）。ペナンブラの前年同期比売上増加率が高い（22.1% vs 12.7%）。ExlService Holdings, Inc.の直近四半期フリーキャッシュフローが多い（$106.5M vs $68.0M）。過去8四半期でペナンブラの売上複合成長率が高い（17.6% vs 11.5%）
ExlService Holdings Inc.は保険、ヘルスケア、銀行・金融サービス、メディア、小売などの業界を対象に分析・デジタルソリューションを提供するグローバル企業で、本社はニューヨークに所在し、米国、欧州、アジア、中南米、オーストラリア、南アフリカなど世界各地に5万4000人以上の専門スタッフを擁しています。
ペナンブラ社は2004年にArani BoseとAdam Elsesserによって設立された米国の医療機器メーカーで、本社はカリフォルニア州アラメダに所在します。脳卒中や動脈瘤などの血管疾患向けの介入治療用機器の開発・製造を主力事業として展開しています。
EXLS vs PEN — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $542.6M | $385.4M |
| 純利益 | $60.2M | $47.3M |
| 粗利率 | 38.6% | 68.0% |
| 営業利益率 | 14.4% | 15.4% |
| 純利益率 | 11.1% | 12.3% |
| 売上前年比 | 12.7% | 22.1% |
| 純利益前年比 | 18.9% | 40.6% |
| EPS（希薄化後） | $0.38 | $1.20 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $542.6M | $385.4M | ||
| Q3 25 | $529.6M | $354.7M | ||
| Q2 25 | $514.5M | $339.5M | ||
| Q1 25 | $501.0M | $324.1M | ||
| Q4 24 | $481.4M | $315.5M | ||
| Q3 24 | $472.1M | $301.0M | ||
| Q2 24 | $448.4M | $299.4M | ||
| Q1 24 | $436.5M | $278.7M |
| Q4 25 | $60.2M | $47.3M | ||
| Q3 25 | $58.2M | $45.9M | ||
| Q2 25 | $66.1M | $45.3M | ||
| Q1 25 | $66.6M | $39.2M | ||
| Q4 24 | $50.7M | $33.7M | ||
| Q3 24 | $53.0M | $29.5M | ||
| Q2 24 | $45.8M | $-60.2M | ||
| Q1 24 | $48.8M | $11.0M |
| Q4 25 | 38.6% | 68.0% | ||
| Q3 25 | 38.5% | 67.8% | ||
| Q2 25 | 37.7% | 66.0% | ||
| Q1 25 | 38.6% | 66.6% | ||
| Q4 24 | 38.1% | 66.8% | ||
| Q3 24 | 37.8% | 66.5% | ||
| Q2 24 | 37.1% | 54.4% | ||
| Q1 24 | 37.4% | 65.0% |
| Q4 25 | 14.4% | 15.4% | ||
| Q3 25 | 14.4% | 13.8% | ||
| Q2 25 | 15.8% | 12.0% | ||
| Q1 25 | 15.7% | 12.4% | ||
| Q4 24 | 14.8% | 13.6% | ||
| Q3 24 | 14.7% | 11.7% | ||
| Q2 24 | 13.7% | -27.0% | ||
| Q1 24 | 14.1% | 4.3% |
| Q4 25 | 11.1% | 12.3% | ||
| Q3 25 | 11.0% | 12.9% | ||
| Q2 25 | 12.8% | 13.3% | ||
| Q1 25 | 13.3% | 12.1% | ||
| Q4 24 | 10.5% | 10.7% | ||
| Q3 24 | 11.2% | 9.8% | ||
| Q2 24 | 10.2% | -20.1% | ||
| Q1 24 | 11.2% | 3.9% |
| Q4 25 | $0.38 | $1.20 | ||
| Q3 25 | $0.36 | $1.17 | ||
| Q2 25 | $0.40 | $1.15 | ||
| Q1 25 | $0.40 | $1.00 | ||
| Q4 24 | $0.31 | $0.88 | ||
| Q3 24 | $0.33 | $0.75 | ||
| Q2 24 | $0.28 | $-1.55 | ||
| Q1 24 | $0.29 | $0.28 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $328.4M | $186.9M |
| 総負債低いほど良い | $298.6M | — |
| 株主資本純資産 | $912.7M | $1.4B |
| 総資産 | $1.7B | $1.8B |
| 負債/資本比率低いほどレバレッジが低い | 0.33× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $328.4M | $186.9M | ||
| Q3 25 | $390.1M | $321.0M | ||
| Q2 25 | $353.3M | $421.8M | ||
| Q1 25 | $331.4M | $376.1M | ||
| Q4 24 | $340.6M | $324.4M | ||
| Q3 24 | $325.8M | $280.5M | ||
| Q2 24 | $276.1M | $288.3M | ||
| Q1 24 | $246.2M | $223.1M |
| Q4 25 | $298.6M | — | ||
| Q3 25 | $354.8M | — | ||
| Q2 25 | $260.0M | — | ||
| Q1 25 | $307.3M | — | ||
| Q4 24 | $288.5M | — | ||
| Q3 24 | $344.7M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $912.7M | $1.4B | ||
| Q3 25 | $952.4M | $1.4B | ||
| Q2 25 | $1.1B | $1.3B | ||
| Q1 25 | $1.0B | $1.2B | ||
| Q4 24 | $929.9M | $1.2B | ||
| Q3 24 | $907.6M | $1.1B | ||
| Q2 24 | $852.6M | $1.2B | ||
| Q1 24 | $803.3M | $1.2B |
| Q4 25 | $1.7B | $1.8B | ||
| Q3 25 | $1.7B | $1.7B | ||
| Q2 25 | $1.7B | $1.7B | ||
| Q1 25 | $1.7B | $1.6B | ||
| Q4 24 | $1.6B | $1.5B | ||
| Q3 24 | $1.6B | $1.5B | ||
| Q2 24 | $1.5B | $1.5B | ||
| Q1 24 | $1.4B | $1.6B |
| Q4 25 | 0.33× | — | ||
| Q3 25 | 0.37× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 0.30× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.38× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $117.4M | $86.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $106.5M | $68.0M |
| FCFマージンFCF / 売上 | 19.6% | 17.7% |
| 設備投資強度設備投資 / 売上 | 2.0% | 4.8% |
| キャッシュ転換率営業CF / 純利益 | 1.95× | 1.83× |
| 直近12ヶ月FCF直近4四半期 | $298.1M | $174.9M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $117.4M | $86.5M | ||
| Q3 25 | $120.7M | $58.3M | ||
| Q2 25 | $109.4M | $44.9M | ||
| Q1 25 | $3.2M | $49.0M | ||
| Q4 24 | $105.3M | $51.1M | ||
| Q3 24 | $110.1M | $56.5M | ||
| Q2 24 | $74.9M | $22.6M | ||
| Q1 24 | $-21.9M | $38.3M |
| Q4 25 | $106.5M | $68.0M | ||
| Q3 25 | $106.4M | $42.0M | ||
| Q2 25 | $95.0M | $29.4M | ||
| Q1 25 | $-9.7M | $35.5M | ||
| Q4 24 | $95.3M | $45.7M | ||
| Q3 24 | $97.3M | $51.0M | ||
| Q2 24 | $62.8M | $18.1M | ||
| Q1 24 | $-33.1M | $32.5M |
| Q4 25 | 19.6% | 17.7% | ||
| Q3 25 | 20.1% | 11.8% | ||
| Q2 25 | 18.5% | 8.7% | ||
| Q1 25 | -1.9% | 11.0% | ||
| Q4 24 | 19.8% | 14.5% | ||
| Q3 24 | 20.6% | 16.9% | ||
| Q2 24 | 14.0% | 6.0% | ||
| Q1 24 | -7.6% | 11.7% |
| Q4 25 | 2.0% | 4.8% | ||
| Q3 25 | 2.7% | 4.6% | ||
| Q2 25 | 2.8% | 4.6% | ||
| Q1 25 | 2.6% | 4.2% | ||
| Q4 24 | 2.1% | 1.7% | ||
| Q3 24 | 2.7% | 1.8% | ||
| Q2 24 | 2.7% | 1.5% | ||
| Q1 24 | 2.6% | 2.1% |
| Q4 25 | 1.95× | 1.83× | ||
| Q3 25 | 2.08× | 1.27× | ||
| Q2 25 | 1.66× | 0.99× | ||
| Q1 25 | 0.05× | 1.25× | ||
| Q4 24 | 2.08× | 1.52× | ||
| Q3 24 | 2.08× | 1.91× | ||
| Q2 24 | 1.63× | — | ||
| Q1 24 | -0.45× | 3.48× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
EXLS
| Insurance | $185.8M | 34% |
| Healthcare And Life Sciences | $142.2M | 26% |
| Banking Capital Markets And Diversified Industries | $122.6M | 23% |
| International Growth Markets | $92.0M | 17% |
PEN
| Thrombectomy | $254.7M | 66% |
| Other | $130.7M | 34% |
